PhysIQ announced today that it entered into a strategic collaboration with InCarda Therapeutics.
Newark, California-based InCarda Therapeutics develops first-of-their-kind inhaled therapies for treating cardiovascular diseases.
IN CASE YOU MISSED IT
- Bayer is making a big digital health play
- B. Braun launches DoseTrac Enterprise infusion management software
- Patient Training is Broken – And Everyone is Paying For It
- Analysts still high on Insulet despite Medtronic’s EOFlow buy, stock market reaction
- Convatec, Beta Bionics partner on iLet bionic pancreas
About Sean Whooley
Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.
